Currently, intratumoral PD-L1 expression remains the only clinically-approved marker to be used prospectively in ICI clinical trials for TNBC [16], which fails to recapitulate the high degree of tumor heterogeneity that TNBC patients exhibit. The gene discussed is CD274; the disease is neoplasm.